TumorDiagnostik & Therapie 2020; 41(06): 380-383
DOI: 10.1055/a-1132-1660
Schwerpunkt Nierenzell- und urologische Tumoren

Aktuelle Systemtherapie beim Nierenzellkarzinom

Peter J. Goebell

In der Vergangenheit war die medikamentöse Therapie des metastasierten oder lokal fortgeschrittenen, nichtoperablen Nierenzellkarzinoms vor allem durch den Einsatz von Tyrosinkinase-Inhibitoren dominiert. Aktuell rücken Checkpoint-Inhibitoren und moderne Multikinase-Inhibitoren in den Vordergrund der Erstlinientherapie.



Publikationsverlauf

Artikel online veröffentlicht:
03. August 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 
  • Literatur

  • 1 Heng DY, Xie W, Regan MM. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-5799
  • 2 Motzer RJ, Bacik J, Murphy BA. et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296
  • 3 Motzer RJ, Mazumdar M, Bacik J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540
  • 4 Goebell PJ, Müller L, Staehler M. et al. Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry. Oncol Res Treat 2017; 40: S3
  • 5 Procopio G, Bamias A, Schmidinger M. et al. Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL Study). Ann Oncol 2018; 29 (Suppl. 08) viii303-viii331
  • 6 Motzer RJ, Tannir NM, McDermott DF. et al. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378: 1277-1290
  • 7 Tannir NM, McDermott DF, Escudier B. et al Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). Journal of Clinical Oncology 2020; 38 (Suppl. 06) 609-609 , doi:10.1200/JCO.2020.38.6_suppl.609
  • 8 Motzer RJ, Hutson TE, McCann L. et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014; 370: 1769-1770
  • 9 Motzer RJ, Nosov D, Eisen T. et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: Results from a phase III trial. J Clin Oncol 2013; 31: 3791-3799
  • 10 Motzer RJ, Escudier B, Powles T. et al. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 2018; 118: 1176-1178
  • 11 Rini BI, Plimack ER, Stus V. et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019; 380: 1116-1127
  • 12 Motzer RJ, Penkov K, Haanen J. et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019; 380: 1103-1115
  • 13 Plimack ER. Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma (RCC): Updated Analysis of KEYNOTE-426. Journal of Clinical Oncology 2020; 38 (Suppl. 15) 5001-5001 , doi:10.1200/JCO.2020.38.15_suppl.5001
  • 14 Choueiri TK, Motzer RJ, Rini BI. et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma [published online ahead of print, 2020 Apr 25]. Ann Oncol 2020; S0923-7534(20)39308-X
  • 15 Motzer RJ, Escudier B, McDermott DF. et al. Nivolumab versus everolimus in advanced renal cell carcinoma. N Engl J Med 2015; 373: 1803-1813
  • 16 Motzer RJ, Hutson TE, Glen H. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicenter trial. Lancet Oncol 2015; 16: 1473-1482